tubepharma.de bewertung und analyse
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Home - |
| Description | Technology & Home Company Services Technology & Products Tubulysins and their synthetic analogs Next generation Epothilones Contact Select Page Home Company Services T |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 217.160.0.2 |
| Location | Germany |
Verwandte Websites
| Site | Rank |
| manga-tube.me | 464,417 |
Mehr zu entdecken
tubepharma.de bewertung
|
Euro€1,102
Zuletzt aktualisiert: 2022-07-03 19:28:33
tubepharma.de hat Semrush globalen Rang von 24,985,756. tubepharma.de hat einen geschätzten Wert von € 1,102, basierend auf seinen geschätzten Werbeeinnahmen. tubepharma.de empfängt jeden Tag ungefähr 551 einzelne Besucher. Sein Webserver befindet sich in Germany mit der IP-Adresse 217.160.0.2. Laut SiteAdvisor ist tubepharma.de sicher zu besuchen. |
Verkehr & Wertschätzungen
| Kauf-/Verkaufswert | Euro€1,102 |
| Tägliche Werbeeinnahmen | Euro€31,958 |
| Monatlicher Anzeigenumsatz | Euro€11,020 |
| Jährliche Werbeeinnahmen | Euro€1,102 |
| Tägliche eindeutige Besucher | 551 |
| Hinweis: Alle Traffic- und Einnahmenwerte sind Schätzungen. | |
DNS Records
| Host | Type | TTL | Data |
| tubepharma.de. | A | 3598 | IP: 217.160.0.2 |
| tubepharma.de. | AAAA | 3598 | IPV6: 2001:8d8:100f:f000::2c7 |
| tubepharma.de. | NS | 86400 | NS Record: ns1081.ui-dns.biz. |
| tubepharma.de. | NS | 86400 | NS Record: ns1081.ui-dns.de. |
| tubepharma.de. | NS | 86400 | NS Record: ns1081.ui-dns.org. |
| tubepharma.de. | NS | 86400 | NS Record: ns1081.ui-dns.com. |
| tubepharma.de. | MX | 3600 | MX Record: 10 mx01.kundenserver.de. |
| tubepharma.de. | MX | 3600 | MX Record: 10 mx00.kundenserver.de. |
HtmlToTextCheckTime:2022-07-03 19:28:33
| Home Company Services Technology & Products Tubulysins and their synthetic analogs Next generation Epothilones Contact Select Page Home Company Services Technology & Products Tubulysins and their synthetic analogs Next generation Epothilones Contact Technology & Products Tubulysins and their synthetic analogs The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour … read more Next generation Epothilones The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated … read more Contact Info 0043 (0) 1 740935 100 wrichter@tubepharma.at Leberstr. 20 A-1110 Wien Austria © 2013 | Tubepharma | |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Type: text/html; charset=UTF-8 Connection: keep-alive Keep-Alive: timeout=15 Date: Thu, 28 Oct 2021 10:31:17 GMT Server: Apache X-Pingback: http://www.tubepharma.de/xmlrpc.php Location: http://www.tubepharma.de/ HTTP/1.1 200 OK Content-Type: text/html; charset=UTF-8 Connection: keep-alive Keep-Alive: timeout=15 Date: Thu, 28 Oct 2021 10:31:17 GMT Server: Apache X-Pingback: http://www.tubepharma.de/xmlrpc.php |